

**Department of Dermatology and Venereology,
Southwest Hospital, Chongqing, China, October 15, 2017**

Treatment of Acne & Rosacea: My Preference

Prof. Dr. med. WenChieh Chen

IZZ Immunologie-Zentrum Zürich, Zurich, Switzerland

Department of Dermatology and Allergy,
Technische Universität München, Munich, Germany

Conflict of Interest



泰尔丝异维A酸胶丸®

肺風粉刺、風刺、面上黑子、面瘡、面皰、婦人 麵粉皺、面瘡、痤瘡

- 內經《素問·生氣通天論》：「汗出見濕，乃生座痹」，
「勞汗當風，寒薄為皺，鬱乃座」
- 隋朝巢元方《諸病源候論》面皰候「面皰者，謂面上有風熱氣生皰，頭如米大，亦如穀大，白色者是也。養生方云：醉不可露臥，令人面發瘡皰。又云：飲酒熱未解，以冷水洗面，令人面發瘡，輕者皺皰。」
- 明朝《普濟方》面粉皺「夫面皺者。是粉刺也。面上有皺如米粒。此由膚腠受於風邪。搏於津脈之氣。因虛而作。亦雲敷之胡散入虛肌。使之然也。」
- 明朝陳實功《外科正宗·肺風粉刺酒渣鼻》「肺風、粉刺、酒皺鼻，三名同種」、「肺風屬肺熱，粉刺、酒渣鼻、酒刺屬脾經，此四名同類，皆由血熱鬱滯不散。又有好飲者，胃中糟粕之味，薰蒸肺臟而成。」
- 清朝乾隆《御纂醫宗金鑑》 肺風粉刺

Treatment of Acne in Traditional Chinese Medicine

Systemic

- 枇杷清肺飲、枇杷葉丸、黃芩清肺飲、防風散、清上防風湯、加味瀉心湯…
- 加味逍遙散、荊芥連翹湯、十味敗毒散…

Topical

- 顛倒散…

Discussion

- D.D. Acne, rosacea, folliculitis/furuncle/carbuncle, granulomas

Acne Pathogenesis

- Acne is a human disease
- Cardinal factors
 - Comedogenesis
 - Seborrhea
 - *Propionibacterium acnes*
 - Inflammation
- Is acne primarily an infectious or inflammatory disease?
- Histology: Acne begins with comedone

Treatment of Acne: Strategy

- Patients

- Age
- Gender
- Acne pattern and severity
- Wishes & Expectations

- Medication

- Efficacy
- Side effects
- Resistance
- Costs

- Physician

- Profit

Treatment Failure of Acne

- Compliance and adherence of patients
 - Expectation
 - Impatience
 - Peer pressure and commercials
- Explanation and reassurance of physicians

Treatment of Acne Comedonica

- Topical treatment
 - Tretinoin Cream, 0.025%, 0.05%, and 0.1%
 - Adapalene 1%/Benzoyl peroxide 2.5%
 - Adapalene 1%
 - ≥ 12 weeks
 - Mostly unacceptable for women
 - Intensive skin care with moisturizers
- Systemic treatment
 - Oral Isotretinoin, 0.1-0.3 mg/kg body weight

Treatment of Acne Papulopustulosa

Topical treatment: No antibiotic monotherapy

- Facial cleansing: Benzoyl peroxide 4% emulsion
- Triclosan 1-2% does not work
- Combination with different active ingredients
 - Clindamycin 1%/Benzoyl peroxide 5%
 - Clindamycin 1%/Tretinoin 0.025%
 - Clindamycin 1% + Benzoyl peroxide 10%
 - Adapalene 1% ± Benzoyl peroxide 2.5%
 - Isotretinoin 0.05%/Erythromycin 2%
 - Erythromycin 4%/Zinc 1.2%
 - Erythromycin 3%/Benzoyl peroxide 5%
 - Metronidazole 1%/2%
 - Azelaic acid 15-20%
 - Erythromycin 2%/4%?
 - Dapsone 7.5% gel?

Treatment of Acne Papulopustulosa

Systemic treatment (combined with topical non-antibiotics)

- Antibiotics
 - Doxycycline 100-200 mg/D
 - Minocycline 50-100 mg/D
 - Azithromycin 250 mg/D (or 500 mg/D, x3 times a week) during pregnancy or breastfeeding
- Combined oral contraceptives
 - Ethinyl estradiol 20 µg/30 µg/35 µg + chlormandionone cyproterone, or drospirenone
- Oral isotretinoin
 - 0.1-0.3 mg/kg/D, for severe acne or acne tarda

Treatment of Acne Papulopustulosa

- Alternative or supplementary treatment
 - Dapsone 50-100 mg/D, contraindicated to antibiotics or isotretinoin
 - Spironolactone 50-100 mg/D, women with virilization
 - Metformin 500-1500 mg/D, obese patients
 - Zinc 30-60 mg/D?

Treatment of Acne Nodulosa/Conglobata

- Systemic treatment
 - Oral isotretinoin 0.3 mg/kg/D x 6-12 months ± oral prednisolone (x 2-4 weeks, tapering from 1 mg/kg/D)
 - Alternative
 - Dapsone
 - Azithromycin
- Topical treatment
 - Potent steroids
 - Prevention of *S. aureus* superinfection

Treatment of Acne Fulminans

- Standard treatment
 - Oral isotretinoin + oral prednisolone
- Cf. SAPHO syndrome, PAPA syndrome
- Alternative treatment
 - Dapsone + oral prednisolone
 - Cyclosporine + oral prednisolone
- Anecdotal treatment
 - TNF α inhibitors?
 - IL-1 β blockers?

Treatment of Acne Tarda

- Oral antibiotics: less effective
- Exclusion of PCO syndrome and insulin resistance
- Treatment of choice
 - Oral isotretinoin ± combined oral contraceptives
- Reluctance and risks of adult women to use oral contraceptives
 - Venous thromboembolism, breast cancer...
 - Melasma in Asian women

Ju Q et al. Clin Dermatol 2017;35:130-7

Use of Oral Isotretinoin: Tips & Traps

- Daily dose: $\leq 0.3 \text{ mg/kg/D}$
- Cumulative dose: 120-150 mg/kg for long-term remission?
 - In one session without interruption?
- Ignorant side effects
 - Ocular
 - Contraindication for pilots due to ocular side effects
 - Meibomian gland dysfunction
 - Corneal thickness-opacity, visual acuity, retinopathy/night blindness
 - Thyroid function
 - Growth: Side effects in high-risk pediatric neuroblastoma
 - Pseudotumor cerebri

Hobbie WL et al. Pediatr Blood Cancer 2011;56:474-6; Karadag AS et al. Dermatology 2015;230:354-9; Uyar B et al. Indian J Dermatol Venereol Leprol 2016;82:587-8; Yıldırım N et al. J Dermatolog Treat 2017;28:141-4

Combined Oral Contraceptives for Acne Treatment

- Efficacy

- COC > Birth control vaginal ring > Mini (progestin only) pills > IUD with progesterone
- NuvaRing®: Etonogestrel 11.7 mg/Ethinyl estradiol 2.7 mg for 3 weeks (etonogestrel 120 µg /ethinyl estradiol 15 µg /D)
- Cerazette®: Desogestrel 75 µg/D
- Mirena® Levonorgestrel 52 mg for 5 years (20 µg/D)

- Evidence

- Generally weak
- Cyproterone acetate 2 mg/ ethinyl estradiol 35 µg
- Chlormadinone acetate 2 mg/ ethinyl estradiol 30 µg
- Drospirenone 3 mg / ethinyl estradiol 20 µg

Combined Oral Contraceptives: Risk of Venous Thromboembolism

- Adjusted odds ratio in current exposure vs. no exposure in the previous year
- To any combined oral contraceptive 2.97 (2.78-3.17, 95% CI)
- To levonorgestrel (2.38, 2.18-2.59), norethisterone (2.56, 2.15-3.06), norgestimate (2.53, 2.17-2.96)
- To cyproterone (4.27, 3.57-5.11), drospirenone (4.12, 3.43-4.96), desogestrel (4.28, 3.66-5.01), gestodene (3.64, 3.00-4.43)
- Annual incidence in Caucasian childbearing women: 10-18 per 10,000
- The number of extra cases per year per 10,000 treated women levonorgestrel (6), norgestimate (6), desogestrel (14), cyproterone (14)

*Vinogradova Y et al. BMJ 2015;350:h2135;
Heit JA, Nat Rev Cardiol 2015;12:464–74*

Nutritional Treatment of Acne?

- Avoidance
 - Low fat, low caloric, low glycemic, low insulinogenic foods?
- Enhancement
 - Green tea/tea polyphenols?
 - omega-3 fatty acid 2,000 mg/ γ -linoleic acid 400 mg/D
 - ...

Jung JY et al. Acta Derm Venereol 2014;94:521-5; Melnik BC. Clin Cosmet Investig Dermatol 2015;8:371-88; Saric S et al. Antioxidants (Basel) 2016;6 pii: E2; Lu PH et al. Complement Ther Med 2016;25:159-63

Treatment of Acne Scar and Pigmentation

- Evidence based?
- Long-term comparison results?
- Identification of scar susceptible patients?
- Ethnic and genetic difference?
- Prevention by early intervention with oral isotretinoin?

Isotretinoin and Timing of Procedural Interventions

- Current recommendation
 - Elective surgery 6-12 months after isotretinoin exposure
 - Isotretinoin increased local level of TGF- β 1
- Challenge
 - Insufficient evidence for delay of manual dermabrasion, superficial chemical peels, cutaneous surgery, laser hair removal, and fractional ablative and nonablative laser procedures
 - Mechanical dermabrasion and fully ablative laser are not recommended
- Discussion
 - Setting: Daily high-dose treatment in early times
 - Depth of injury

Spring LK et al. JAMA Dermatol 2017;153:802-9; Tolkachjov SN et al. J Am Acad Dermatol 2017;77:159-61; Leivo T et al. Skin Pharmacol Appl Skin Physiol 2000;13:150-6



Rosacea Pathogenesis

- Unclear, polygenic multifactorial
- Pathogenic factors
 - Vasodilatation
 - Inflammation
 - Demodex mites
 - Sebaceous hyperplasia
 - ...

Rosacea Begins with Facial Erythema

Regulation of cutaneous circulation

- Adrenoceptors
 - α_{1A} -, α_{1D} -, $\alpha_{2A/D}$ -, and α_{2B} -receptor subtypes: vasoconstriction
 - β_2 -receptor: vasodilation
 - Activation by circulating norepinephrine
- Neurotransmitters
 - Vasoconstriction: norepinephrine, neuropeptide Y
 - Active vasodilatation: unclear
 - Cholinergic innervation: acetylcholine?
 - Other potential mediators: NO, substance P, histamines, prostaglandins

Rosacea Treatment: Strategy

- Stage adjusted and adapted
- Rosacea classification and staging
 - Rosacea subtypes, progressive and overlapping
 - ROSCO panel?
 - Ethnic and genetic difference?
 - D.D. Primary demodicosis

Tan J et al. Br J Dermatol 2017;176:431-8

Primary Demodicosis without Facial Erythema



Chen W, Plewig G. Br J Dermatol 2014;170:1219-25

Treatment of Rosacea Erythema

- Topical treatment
 - Brimonidine tartrate 5% gel (Mirvaso ®), α_{2A} -adrenoceptor agonist
 - Oxymetazoline hydrochloride 1% cream (Rhofade ®), α_{1A} -adrenoceptor agonist
 - Continual or episodic use?
 - Rebound phenomenon
 - Tachyphylaxis
- Systemic treatment
 - Clonidine (Moxonidine?), α_{2A} -adrenoceptor agonist
 - Carvedilol, nonselective β blocker on α_1 -, β_1 - und β_2 -adrenoceptors

Hsu CC, Lee JY. Arch Dermatol 2011;147:1258-60

Rebound Erythema After Topical Brimonidine Treatment



Ilkovitch D et al. J Am Acad Dermatol 2014;70:e109-10

Treatment of Rosacea Erythema

- Alternative treatment
 - Laser treatment?
 - Botox treatment?
 - Evidence and long-term efficacy?
- Persistent erythema
 - Oral isotretinoin?
- Can early treatment prevent the progression of rosacea?

Persistent Erythema in Rosacea with Secondary Demodicosis



Treatment of Rosacea Papulopustulosa

- Topical treatment
 - Azelaic acid 20% cream/15% gel
 - Metronidazole 0.75%, 1%, 2% cream
 - Ivermectin 1% cream
 - Erythromycin 2%/4% cream
- Systemic treatment
 - Doxycycline 50-100 mg/D
 - Minocycline 50-100 mg/D
 - Erythromycin 500 mg TID
 - Azithromycin 250 mg/D
 - Isotretinoin 0.1-0.3 mg/kg/D

Treatment of Rosacea Phyma

- Laser treatment
- Surgical treatment
- Can early use of oral isotretinoin prevent the formation of phyma?

Treatment of Rosacea Fulminans

- Standard treatment
 - Oral isotretinoin + systemic glucocorticoids
- Alternative treatment
 - Dapsone
 - Azithromycin

Rosacea Fulminans in Pregnancy

32-year-old, primigravida, 16. gestational week



Treatment of Childhood Rosacea

- The same principle, but less evidence based
- Special variant: Idiopathic facial aseptic granuloma (IFAG)?
 - Rosacea nodulosa/conglobata?
 - Oral erythromycin or doxycycline + topical metronidazole cream
 - Long-term follow-up failed

Boralevi F et al. Br J Dermatol 2007;156:705-8

Childhood Rosacea



Idiopathic Facial Aseptic Granuloma (IFAG)



*Martinez-Diaz GJ et al. Dermatol
Online J 2010;16:9*

Morbihan Disease

- Degos R, Civatte J, Beauve-Méry. Nouveau cas d'œdème érythémateux faciale chronique. Bull Soc Franc Derm Syph 1973;80:257
- Connelly MG, Winkelmann RK. Solid facial edema as a complication of acne vulgaris. Arch Dermatol 1985;121:87-90
- Jungfer B, Jansen T, Przybilla B, Plewig G. Solid persistent facial edema of acne: successful treatment with isotretinoin and ketotifen. Dermatology 1993;187:34-7



Morbihan Disease



Treatment of Morbihan Disease

- Oral isotretinoin
 - High dose 0.5-0.7 mg/kg/D
 - Moderate dose 0.3-0.5 mg/kg/D + Ketotifen 1 mg/D
- Doxycycline or Minocycline
- Thalidomide?
- Clofazimine?

Hölzle E et al. Hautarzt 1995;46:796-8; Okubo A et al. J Dermatol 2017;44:713-6; Smith LA et al. Arch Dermatol 2012;148:1395-8

Conclusions

- Topical cocktail therapy
- Oral antibiotics plus topical retinoids
- Oral isotretinoin
 - The most effective treatment for acne and rosacea in different subtypes
 - Trends: Daily low-dose for 1-2 years
 - Serious concern in Asia due to inadequate contraception
 - Hesitation to use combined oral contraceptives
- Early and unselective use of oral isotretinoin
 - Avoidance in children esp. before puberty
 - Avoidance in pilots, soldiers and professional drivers

Thank you very much!

